STANDARD OPERATING PROCEDURE (SOP) FOR SARS-CoV-2 REAL-TIME RT-PCR TESTING LABORATORY

CONTENTS

1. Scope  
2. Personnel  
3. Accommodation and environmental conditions  
4. Equipment  
5. Test method and method verification  
6. Sampling  
7. Handling of test items  
8. Examination of procedure  
9. Assuring the quality of test results  
10. Interpretation and Reporting the results  
11. Waste management  
12. Risk Management  

References  
Acknowledgement
1. Scope

1.1 This document describes the requirements to be complied by the laboratories offering Real-time RT-PCR test for SARS-CoV-2 virus detection. The guideline, requirement and performance criteria outlined in this document are intended for comparable, accurate and reproducible results.

1.2 The laboratory intending to apply for SARS-CoV-2 RT-PCR testing shall be a under supervision by a clinical microbiologist officially appointed by the laboratory and:

   a) have been accredited for medical testing under ISO15189 for microbiology molecular testing or

   b) have offered medical microbiology molecular testing on human samples as one of the testing scopes.

2. Personnel

2.1 Personnel taking the samples

   The personnel taking the samples of nasopharyngeal and oropharyngeal swabs must be a registered medical practitioner who has attended training and has a certificate of attendance for Sample Taking and Handling Training for COVID-19 for General Practitioners and Paramedics from Private Health Facilities issued by the Family Health Development Division, MOH or State / Federal Health Department.

   Sampling can only be done by the Private Healthcare Facilities and Services registered or licensed under Act 586 at the premises or
elsewhere that has been approved for the facilities by the Medical Practice Division, Ministry of Health Malaysia.

2.2 Personnel conducting the tests
The personnel conducting the test procedure shall have the qualifications, training, and experience appropriate to the tasks performed. The personnel shall have a minimum Diploma in Medical Laboratory Technology with experience of performing nucleic acid testing of at least 3 months. Training and competency in nucleic acid testing methods shall also be documented.

2.3 Authorized signatory
The laboratory shall have qualified, skilled and experienced signatory (ies) to validate data and troubleshoot problems. Approved signatory (ies) shall have a degree or higher in the microbiology field, trained and competent in the nucleic acid method, with at least one year or more laboratory working experience and at least 3 months working experience in the current laboratory. For those with less than 1-year laboratory working experience shall have at least 6 months working experience in the current laboratory. Trained and competent Pathologist or Scientific Officer in Nucleic Acid Testing are also allowed to validate the result.
3. Accommodation and environmental conditions
The laboratory shall have dedicated areas for specimen reception, pre and post analysis to minimize cross-contamination. There shall be separate room for pre-PCR, reagent preparation and PCR amplification. The laboratory that has fully automated system, such as from extraction to master-mix preparation, need not have separate room.

3.1 Specimen storage
There shall be a designated space for storage of specimens, as specified in the Guidelines on COVID-19 Management in Malaysia. Specimens shall not be placed in the same storage as the reagents. Pre-testing samples shall not be kept together with post-testing samples.

3.2 Reagents storage
Reagents shall be stored at the appropriate temperature as recommended by the manufacturer. There shall be an inventory on the date of receive, lot number, expiry date and date of the kit in use. Each new lot of the kit or any changes in reagents or procedures shall be verified for performance before use in testing and documented.
4. Equipment

4.1 All freezers and chillers shall have daily temperature chart monitoring.

4.2 All equipment including biosafety cabinet class II shall be maintained according to the planned preventive maintenance (PPM).

4.3 Autoclaves shall be operated by trained personnel.

5. Test method and method verification

5.1 The laboratory shall use kits that have been validated by Institute for Medical Research (IMR) or National Public Health Laboratory (NPHL). The list of recommended kits can be obtained from Medical Device Authority (MDA).

5.1 The laboratory shall perform verification of the test method before offering the test. Records of all verifications shall be safely stored for future reference.

5.3. The procedure for offering SARS-CoV-2 Real Time RT-PCR test are as follows:

i. To completely fill up an application form to conduct the test and to submit the form to the Secretariat of Jawatankuasa Pasukan Khas Makmal COVID-19 (JPKMCovid-19) at covid19makmal@moh.gov.my (Annex 4f). This form is available at http://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm.
ii. A site visit shall be carried out by the committee, to determine the feasibility of the laboratory to offer the service upon application.

iii. Laboratory shall be given 14 working days to take and submit corrective actions to the Secretariat for the non-conformity found during the site visit.

iv. Blinded samples shall be provided to the laboratory that has passed the site visit.

v. The testing assay shall have at least two (2) different targets on the COVID-19 virus genomes, of which at least one target is confirmatory for COVID-19 virus, following the recommendations and updates by WHO from time to time.¹

vi. Upon completion of PCR, e-mail the report containing the Ct value and image of the PCR amplification curve of each sample, as well as the interpretation of the results to evaluating laboratory accordingly (IMR or MKAK).

vii. Approval shall be given to the requesting laboratory by the Chairman of JPKMCOVID-19 after a successful technical evaluation process.

viii. Once approved to conduct the test, the laboratory may proceed to test using actual clinical samples. The laboratory shall email the PCR images of the first 5 positive and 5 negative clinical samples and send those samples (minimum 500 µl) to IMR/MKAK for verification.
ix. All positive samples shall be kept at -80°C for retesting if necessary.

x. If the laboratory is not approved to conduct the test, re-application for offering SARS-CoV-2 Real Time RT-PCR testing to the JPKMCovid-19 can only be made after 2 months from date of un-approved notice.

xi. The authorized list of laboratories shall be kept by the Secretariat and updated regularly.

6. Sampling

6.1 Staff shall be trained for appropriate personal protective equipment (PPE) usage, specimen collection, storage, packaging and transport before collecting the samples.

Specimens

Specimens shall be collected from:

a) lower respiratory tract such as sputum (if produced) or tracheal aspirate or bronchoalveolar lavage

or

b) upper respiratory tract specimens such as nasopharyngeal AND oropharyngeal swabs or nasopharyngeal wash / aspirate

6.2 All swab samples shall be placed in viral transport media (VTM) or universal transport media and kept at 2-8°C before processing.
6.3 Request forms and specimens shall be labelled with at least 2 unique identifiers to ensure traceability of the specimens.

6.4 The traceability of all sampling activities from receipt through preparation, proper analysis, reporting of results, storage to disposal of the samples shall be documented.

7. Specimen Management

7.1 Packaging and Transportation
Specimens shall be packed in triple packaging and transported at 2-8°C. The request forms shall be placed separately on the outside package. Refer to Guidelines on COVID-19 Management in Malaysia.

7.2 Handling of specimens
Specimens shall be processed in biosafety cabinet class II and handled by staff wearing proper PPE.

8. Examination procedure
The laboratory shall have a standard operating procedure for conducting the real-time RT-PCR. All worksheets related to the testing shall be kept and maintained for retention of record.

9. Assuring the quality of test results
9.1 Each test run shall include positive and negative control.
9.2 The laboratory shall also participate in the External Quality Assurance Programme. The laboratory shall achieve at least 80% overall correct results. If the result is unsatisfactory, the laboratory shall give evidence of corrective actions taken.

9.3 The laboratory shall conduct internal audit of the test at least once a year and corrective actions taken where necessary and documented.

9.4 All SARS-CoV-2 RT-PCR testing laboratories shall be audited at least once a year by the committee.

10. **Interpretation and Reporting of results**

10.1 The interpretation of results shall be based on manufacturer's instruction as outlined in the kit insert.

10.2 All results shall be reviewed and validated by authorized personnel (approved signatories) prior to release.

10.3 All results shall be keyed into the *Sistem Informasi Makmal Kesihatan Awam* Outbreak (SIMKA Outbreak).

10.4 It is mandatory to report all positive results into SIMKA Outbreak within 24hrs.

10.5 All negative results shall be reported into SIMKA Outbreak within 48hrs.

11. **Waste management**

The laboratory shall have waste management procedure in place. All clinical samples and consumables used shall be autoclaved or incinerated.
12. Risk Management

The laboratory shall have risk assessment activities for performing SARS-CoV-2 RT-PCR testing.

References

2. WHO recommendation for testing specimens for COVID-19.
3. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases. Interim guidance 19th March, WHO.
Acknowledgements

Dr. Hishamshah bin Mohd Ibrahim
Deputy Director General of Health (Research and Technical Support)

*Institute for Medical Research*
- Dr Norazah Ahmad
- Dr Ravindran Thayan
- Dr Rozainanee Mohd Zain
- Dr Rohaidah Hashim

*National Public Health Laboratory*
- Dr Hani Mat Husin
- Dr Donal Huda Nasril
- Dr Wan Amani Wan Abdul Azim

*MOH Hospitals*
- Dr Arni Talib
- Dr Tengku Norita Tengku Yazid
- Dr Noraini Ismail
- Dr Salmah Idris
- Dr Nur Izati Mustapa

*National Cancer Institute*
- Dr Suhaila Md Hanapiah

*Medical Development Division*
- Dr Mawaddah Ghazali
- Dr Olivia Tan Yen Ping
INQUIRIES

Any inquiries about this document can be referred to:

Jawatankuasa Pasukan Khas Makmal COVID-19 (JPKMCOVID-19)
Medical Development Division
Level 5, Block E, Parcel E,
Federal Government Administrative Centre
62590 Putrajaya
Tel : 03-8883 1489 / 03-8890 6028
Email : covid19makmal@moh.gov.my